🔎 Search anything on the website

PointCross Blog

SEND Dataset Automation: Cutting Weeks Off Nonclinical Reporting

SEND (Standard for Exchange of Nonclinical Data) is the CDISC data format the FDA requires for most nonclinical safety study submissions, mandatory for NDAs since December 2016 and INDs since December 2017. SEND dataset automation means generating that submission-ready dataset directly from the study's operating record as data is collected, instead of reconstructing it...

Why Submission Dataset Validation Breaks

PointCross Life Sciences has standardized nonclinical study data for FDA and PMDA submissions since 2009, and in that time one pattern has repeated itself across sponsors of every size: the submission package clears the validator, the team exhales, and six weeks later an FDA reviewer flags the data as unusable. The validator was never...

What Causes SDTM, ADaM and SEND Validation Failures

SDTM, ADaM, and SEND datasets form the backbone of regulatory submissions to the FDA, PMDA, and other agencies. Yet validation failures in these datasets remain one of the most common obstacles to achieving submission readiness. Understanding why these failures occur helps clinical data managers and operations leaders address root causes rather than just fixing...

PointCross Life Sciences Co-Hosted PHUSE Single Day Event in Foster City, CA

PointCross Life Sciences is proud to co-host the PHUSE Single Day Event (SDE) alongside Gilead Sciences on August 6, 2026, in Foster City, California. Centered around the theme, “Real-World Impact of Where AI Technology and Preclinical and Clinical Computation Meet,” the event will bring together industry leaders, researchers, and technology innovators to discuss how artificial...

SEND Validation for FDA and PMDA in 2026

Why SEND Validation Matters for Your FDA and PMDA Submissions Your nonclinical study data must clear FDA validation before a reviewer ever sees it. A malformed dataset, missing Trial Summary file, or mismatch between your SEND package and study report can trigger a refuse-to-file decision that delays your entire program by weeks or months. The Standard...

SEND Datasets: The Complete Guide

SEND datasets are the standardized, machine-readable files the U.S. FDA requires for nonclinical study data in most drug and biologics submissions. If you run toxicology studies, assemble regulatory filings, or manage data at a CRO, SEND datasets are no longer optional for in-scope studies. This guide explains what SEND is, who needs it, which...

SEND 4.0 Is Coming. Here’s What You Actually Need to Know. 

CDISC opened public review for SENDIG v4.0 in April 2026, with publication targeted for Q4 2026. While the FDA has not yet announced an implementation timeline, many CROs and sponsors are watching from a distance.  That posture has a cost.  SENDIG v4.0 isn't just another version update. It introduces some of the most significant structural changes since its original release. The changes extend far beyond routine version...

Mitigating risk with PointCross 

As some may have heard, the FDA released their bi-annual update to the Technical Conformance Guide earlier this year. Along with slight corrections and improvements, an entire Appendix was added regarding SEND data review "Best Practices". With the update, the FDA has formalized some industry wide best practices; better quality SEND datasets equates to...

5 SEND Compliance Challenges Nonclinical CROs Must Solve

This article breaks down the real SEND compliance challenges that nonclinical CROs face, grounded in current FDA and CDISC requirements, and shows where disciplined process and the right tooling change the outcome. We write this for toxicologists, regulatory affairs professionals, bioinformaticians, pharma and biotech executives, and the IT and data teams who live with...